NZ531534A - Angiotensin peptides conjugated with a carrier comprising a virus-like particle - Google Patents

Angiotensin peptides conjugated with a carrier comprising a virus-like particle

Info

Publication number
NZ531534A
NZ531534A NZ531534A NZ53153402A NZ531534A NZ 531534 A NZ531534 A NZ 531534A NZ 531534 A NZ531534 A NZ 531534A NZ 53153402 A NZ53153402 A NZ 53153402A NZ 531534 A NZ531534 A NZ 531534A
Authority
NZ
New Zealand
Prior art keywords
angiotensin
virus
conjugate
seq
bacteriophage
Prior art date
Application number
NZ531534A
Other languages
English (en)
Inventor
Martin Bachmann
Original Assignee
Cytos Biotechnology Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/050,902 external-priority patent/US7264810B2/en
Application filed by Cytos Biotechnology Ag filed Critical Cytos Biotechnology Ag
Publication of NZ531534A publication Critical patent/NZ531534A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5409—IL-5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/082—Hepadnaviridae (F), e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
NZ531534A 2001-10-05 2002-10-07 Angiotensin peptides conjugated with a carrier comprising a virus-like particle NZ531534A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US32699801P 2001-10-05 2001-10-05
US33104501P 2001-11-07 2001-11-07
US10/050,902 US7264810B2 (en) 2001-01-19 2002-01-18 Molecular antigen array
PCT/IB2002/000166 WO2002056905A2 (en) 2001-01-19 2002-01-21 Molecular antigen array
US39663702P 2002-07-19 2002-07-19
PCT/EP2002/011219 WO2003031466A2 (en) 2001-10-05 2002-10-07 Angiotensin peptide-carrier conjugates and uses thereof

Publications (1)

Publication Number Publication Date
NZ531534A true NZ531534A (en) 2005-10-28

Family

ID=27517536

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ531534A NZ531534A (en) 2001-10-05 2002-10-07 Angiotensin peptides conjugated with a carrier comprising a virus-like particle

Country Status (8)

Country Link
EP (1) EP1432443B1 (https=)
JP (1) JP4671389B2 (https=)
CN (1) CN1558774B (https=)
AU (1) AU2002362696B2 (https=)
CA (1) CA2462857C (https=)
ES (1) ES2321491T3 (https=)
NZ (1) NZ531534A (https=)
WO (1) WO2003031466A2 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
AU2002339224B2 (en) 2001-09-14 2008-10-09 Kuros Us Llc Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
MXPA04011247A (es) * 2002-07-19 2005-02-17 Cytos Biotechnology Ag Conjugados portadores de grelina.
EP1605972A2 (en) 2003-03-26 2005-12-21 Cytos Biotechnology AG Hiv-peptide-carrier-conjugates
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
EP1706152A2 (en) * 2004-01-20 2006-10-04 Cytos Biotechnology AG Particle-induced ghrelin immune response
CA2580208A1 (en) * 2004-09-21 2006-03-30 Cytos Biotechnology Ag Virus-like particles comprising a fusion protein of the coat protein of ap205 and an antigenic polypeptide
WO2006037787A2 (en) 2004-10-05 2006-04-13 Cytos Biotechnology Ag Vlp-antigen conjugates and their uses as vaccines
US20070160628A1 (en) * 2005-08-31 2007-07-12 Birkett Ashley J Stabilized virus-like particles and epitope display systems
CN101267834B (zh) * 2005-09-28 2013-06-05 赛托斯生物技术公司 白介素-1偶联物及其用途
CN101300775B (zh) * 2005-10-31 2012-12-19 松下电器产业株式会社 安全处理装置、安全处理方法、加密信息嵌入方法、程序、存储介质和集成电路
EP1973608A1 (en) 2005-12-14 2008-10-01 Cytos Biotechnology AG Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
MX2008015529A (es) 2006-06-12 2009-01-13 Cytos Biotechnology Ag Procesos para empacar oligonucleotidos en particulas similares a virus de bacteriofagos de arn.
JP2008007482A (ja) * 2006-06-30 2008-01-17 Univ Of Miyazaki 昇圧作用を有する新規ポリペプチド
WO2009056651A1 (en) * 2007-11-02 2009-05-07 Cytos Biotechnology Ag Angiotensin-carrier formulation
JP2009137859A (ja) * 2007-12-05 2009-06-25 Univ Nihon マウス多量体免疫グロブリンレセプターに反応するモノクローナル抗体
PE20161551A1 (es) 2009-09-03 2017-01-18 Pfizer Vaccines Llc Vacuna de pcsk9
EP2698164B1 (en) 2011-04-15 2018-04-04 Osaka University Dna vaccine
WO2013092720A1 (en) 2011-12-22 2013-06-27 F. Hoffmann-La Roche Ag Full length antibody display system for eukaryotic cells and its use
KR102205077B1 (ko) 2012-08-31 2021-01-20 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 Ｖｅｇｆ-특이적 에피토프 및/또는 안지오포이에틴-2-특이적 에피토프를 함유하는 ｄｎａ 백신
JP6001974B2 (ja) 2012-09-21 2016-10-05 アンジェスＭｇ株式会社 アポリポプロテイン（ａ）の特異的エピトープを含むＤＮＡワクチン
ES2854726T3 (es) 2015-10-30 2021-09-22 The Univ Of Copenhagen Partícula similar a virus con presentación eficiente de epítopos
EP4132478A1 (en) 2020-04-09 2023-02-15 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
CN119789863A (zh) 2022-08-30 2025-04-08 赛巴动物健康股份有限公司 经修饰的cmv病毒样颗粒

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA934199B (en) * 1992-06-18 1994-01-10 Akzo Nv Carrier system against gnrh
NZ501832A (en) * 1997-06-24 2002-12-20 Proteus Molecular Design Angiotensin-peptide carrier conjugates for treating diseases associated with the renin-angiotensin system
ATE314095T1 (de) * 1998-10-21 2006-01-15 Us Health Virusähnliche partikel zur induktion von autoantikörpern
NZ512456A (en) * 1998-11-30 2003-10-31 Cytos Biotechnology Ag Ordered molecular presentation of antigens
CA2407897A1 (en) * 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines

Also Published As

Publication number Publication date
ES2321491T3 (es) 2009-06-08
AU2002362696B2 (en) 2008-05-29
JP4671389B2 (ja) 2011-04-13
AU2002362696A2 (en) 2003-04-22
JP2005514333A (ja) 2005-05-19
WO2003031466A3 (en) 2003-10-23
EP1432443A2 (en) 2004-06-30
CA2462857C (en) 2012-01-24
CA2462857A1 (en) 2003-04-17
CN1558774A (zh) 2004-12-29
EP1432443B1 (en) 2009-01-21
CN1558774B (zh) 2012-03-14
WO2003031466A2 (en) 2003-04-17

Similar Documents

Publication Publication Date Title
US7115266B2 (en) Angiotensin peptide-carrier conjugates and uses thereof
AU2002362696B2 (en) Angiotensin peptide-carrier conjugates and uses thereof
US8187607B2 (en) Hapten-carrier conjugates and uses thereof
AU2002362696A1 (en) Angiotensin peptide-carrier conjugates and uses thereof
CA2433316C (en) Molecular antigen array
EP2351770A1 (en) Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
US20070248617A1 (en) Medical Uses of Carrier Conjugates of Non-Human Tnf -Peptides
US20080019991A1 (en) Carrier Conjugates Of Tnf-Peptides
US20050191317A1 (en) Ghrelin-carrier conjugates
JP2010189406A (ja) アンジオテンシンペプチド−担体複合体およびその使用
RU2350622C2 (ru) Конъюгат ангиотензиновой пептидной составляющей с носителем, композиция вакцины, способ иммунизации животного и способ лечения или профилактики физического нарушения, ассоциированного с активируемой ренином ангиотензиновой системой
HK1067057B (en) Angiotensin peptide-carrier conjugates and uses thereof
AU2002228263B2 (en) Molecular antigen array
AU2002228263A1 (en) Molecular antigen array

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed